Semaglutide ndi mankhwala ochepetsa shuga opangidwa ndi Novo Nordisk pochiza matenda amtundu wa 2. Mu June 2021, a FDA adavomereza Semaglutide kuti azigulitsa ngati mankhwala ochepetsa thupi (dzina la malonda Wegovy). Mankhwalawa ndi glucagon-ngati peptide 1 (GLP-1) receptor agonist omwe amatha kutsanzira zotsatira zake, kuchepetsa njala, motero amachepetsa kudya ndi kudya kwa calorie, motero ndi othandiza pakuwonda.
Kuphatikiza pa kugwiritsidwa ntchito pochiza matenda a shuga a 2 ndi kunenepa kwambiri, Semaglutide yapezekanso kuti imateteza thanzi la mtima, kuchepetsa chiopsezo cha khansa, ndikuthandizira kusiya kumwa. Kuonjezera apo, kafukufuku wina waposachedwapa wasonyeza kuti Semaglutide ikhoza kuchepetsanso chiopsezo cha matenda aakulu a impso ndi matenda a Alzheimer's.
Kafukufuku wam'mbuyomu wasonyeza kuti kuwonda kumatha kuthetsa zizindikiro za mafupa a bondo (kuphatikizapo kupweteka kwa ululu). Komabe, zotsatira za GLP-1 receptor agonist kuwonda mankhwala monga Semaglutide pa zotsatira za knee osteoarthritis mwa anthu onenepa sanaphunzire mokwanira.
Pa Okutobala 30, 2024, ofufuza ochokera ku Yunivesite ya Copenhagen ndi Novo Nordisk adasindikiza pepala lofufuzira lotchedwa: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis in the New England Journal of Medicine (NEJM), magazini yapamwamba yazachipatala padziko lonse lapansi.
Kafukufuku wachipatalayu adawonetsa kuti semaglutide imatha kuchepetsa kwambiri kulemera kwake ndikuchepetsa kwambiri ululu womwe umabwera chifukwa cha kunenepa kwambiri kwa nyamakazi yokhudzana ndi kunenepa kwambiri (analgesic effect ndi yofanana ndi ya opioids), ndikuwongolera kuthekera kwawo kuchita nawo masewera. Aka ndi nthawi yoyamba kuti mtundu watsopano wa mankhwala ochepetsa thupi, GLP-1 receptor agonist, watsimikiziridwa kuti amachiza nyamakazi.
Nthawi yotumiza: Feb-27-2025